Ongoing mutational processes lead to the generation of cancer neoantigens that are potentially recognised by tumour-fighting effector cells such as natural killer (NK) cells, cytotoxic CD8+ T, and CD4+ Th1 lymphocytes that activate a powerful anti-tumour immune response that is able to achieve substantial tumour debulking [3,4,5]. The gene discussed is CD8A; the disease is cancer.